These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12975561)

  • 1. Treatment of acute bleeding with recombinant factor VIIa in a patient with IgA deficit receiving anticoagulant therapy.
    Sanchis Cervera J; Andrés Blasco CJ; Mena-Duran AV
    Acta Haematol; 2003; 110(1):51-2. PubMed ID: 12975561
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.
    Dao A; Tuan B; Carlson N
    Am J Med; 2005 Oct; 118(10):1172-3. PubMed ID: 16194652
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.
    Vavra KA; Lutz MF; Smythe MA
    Ann Pharmacother; 2010 Apr; 44(4):718-26. PubMed ID: 20233918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NovoSeven in warfarin-treated patients.
    Berntorp E; Stigendal L; Lethagen S; Olofsson L; Hedner U
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S113-5. PubMed ID: 10850575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated recombinant factor VII to reverse oral anticoagulants for emergent cesarean delivery.
    Morante L; Guasch EV; Palacio F; Gilsanz F
    Anesth Analg; 2006 Jun; 102(6):1902-3. PubMed ID: 16717350
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond.
    Franchini M; Crestani S; Frattini F; Sissa C; Bonfanti C
    Semin Thromb Hemost; 2015 Apr; 41(3):342-7. PubMed ID: 24937097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iatrogenic causes of an ICH: OAT therapy.
    Iorio A
    Eur J Anaesthesiol Suppl; 2008; 42():8-11. PubMed ID: 18289410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux.
    Luporsi P; Chopard R; Janin S; Racadot E; Bernard Y; Ecarnot F; Séronde MF; Briand F; Guignier A; Descotes-Genon V; Meneveau N; Schiele F
    Acute Card Care; 2011 Jun; 13(2):93-8. PubMed ID: 21517672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
    Le Roux P; Pollack CV; Milan M; Schaefer A
    J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of traumatic bleeding with recombinant factor VIIa.
    Kenet G; Walden R; Eldad A; Martinowitz U
    Lancet; 1999 Nov; 354(9193):1879. PubMed ID: 10584732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies of anticoagulation reversal in life-threatening bleeds.
    Rolfe S; Papadopoulos S; Cabral KP
    J Pharm Pract; 2010 Jun; 23(3):217-25. PubMed ID: 21507817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated factor VII for treatment of enoxaparin-induced bleeding.
    Hu Q; Brady JO
    Mayo Clin Proc; 2004 Jun; 79(6):827. PubMed ID: 15182101
    [No Abstract]   [Full Text] [Related]  

  • 13. Stop the Bleeding! Reversing the Effects of Direct-acting Oral Anticoagulants.
    Fischer J
    S D Med; 2016 Nov; 69(11):516-517. PubMed ID: 28810116
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant factor VIIa treatment of bleeding associated with acute renal failure.
    Moisescu E; Ardelean L; Simion I; Mureşan A; Ciupan R
    Blood Coagul Fibrinolysis; 2000 Sep; 11(6):575-7. PubMed ID: 10997798
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant factor VIIa use following massive pulmonary hemorrhage after CPB.
    Courtney H
    Paediatr Anaesth; 2009 Mar; 19(3):272. PubMed ID: 19236650
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of bleeding with recombinant factor VIIa in a patient with extensive burns.
    Bianchi A; Jackson D; Maitz P; Thanakrishnan G
    Thromb Haemost; 2004 Jan; 91(1):203-4. PubMed ID: 14691589
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.
    Eerenberg ES; Middeldorp S; Levi M; Lensing AW; Büller HR
    J Thromb Haemost; 2015 Sep; 13(9):1590-6. PubMed ID: 26179293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin reversal.
    Hanley JP
    J Clin Pathol; 2004 Nov; 57(11):1132-9. PubMed ID: 15509671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa in severe uremic bleeding.
    Révész T; Arets B; Bierings M; van den Bos C; Duval E
    Thromb Haemost; 1998 Aug; 80(2):353. PubMed ID: 9716175
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux.
    Bordes J; Asencio Y; Kenane N; Fesselet J; Meaudre E; Goutorbe P
    Br J Anaesth; 2008 Oct; 101(4):575-6. PubMed ID: 18782890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.